Reprogramming Immunometabolism: Ofirnoflast & GLP-1 Synergy in the Next Generation of Obesity Therapies
Time: 3:10 pm
day: Day One
Details:
- A Dual-Targeted Strategy: Combining the metabolic effects of GLP-1 receptor agonists with Ofirnoflast’s direct inhibition of the NEK7-NLRP3 inflammasome tackles both appetite regulation and the chronic inflammation that underlies obesity and insulin resistance
- Enhanced Weight Loss and Glycemic Control: Preclinical studies demonstrate true synergy between Ofirnoflast and semaglutide, yielding superior reductions in weight, inflammatory markers, and glycemic control compared to either agent alone
- Beyond Weight: Disease Modification and Organ Protection: This combination offers the potential not only to accelerate and deepen weight loss but to reverse adipose dysfunction, preserve beta-cell function, and mitigate inflammation-driven comorbidities like cardiovascular, renal, and liver disease
Speakers:
